The complex of PAMAM-OH dendrimer with Angiotensin (1-7) prevented the disuse-induced skeletal muscle atrophy in mice

Int J Nanomedicine. 2017 Mar 13:12:1985-1999. doi: 10.2147/IJN.S125521. eCollection 2017.

Abstract

Angiotensin (1-7) (Ang-(1-7)) is a bioactive heptapeptide with a short half-life and has beneficial effects in several tissues - among them, skeletal muscle - by preventing muscle atrophy. Dendrimers are promising vehicles for the protection and transport of numerous bioactive molecules. This work explored the use of a neutral, non-cytotoxic hydroxyl-terminated poly(amidoamine) (PAMAM-OH) dendrimer as an Ang-(1-7) carrier. Bioinformatics analysis showed that the Ang-(1-7)-binding capacity of the dendrimer presented a 2:1 molar ratio. Molecular dynamics simulation analysis revealed the capacity of neutral PAMAM-OH to protect Ang-(1-7) and form stable complexes. The peptide coverage ability of the dendrimer was between ~50% and 65%. Furthermore, an electrophoretic mobility shift assay demonstrated that neutral PAMAM-OH effectively bonded peptides. Experimental results showed that the Ang-(1-7)/PAMAM-OH complex, but not Ang-(1-7) alone, had an anti-atrophic effect when administered intraperitoneally, as evaluated by muscle strength, fiber diameter, myofibrillar protein levels, and atrogin-1 and MuRF-1 expressions. The results of the Ang-(1-7)/PAMAM-OH complex being intraperitoneally injected were similar to the results obtained when Ang-(1-7) was systemically administered through mini-osmotic pumps. Together, the results suggest that Ang-(1-7) can be protected for PAMAM-OH when this complex is intraperitoneally injected. Therefore, the Ang-(1-7)/PAMAM-OH complex is an efficient delivery method for Ang-(1-7), since it improves the anti-atrophic activity of this peptide in skeletal muscle.

Keywords: anti-atrophic peptide; carrier; muscle wasting; peptide delivery.

MeSH terms

  • Angiotensin I / pharmacology
  • Angiotensin I / therapeutic use*
  • Animals
  • Dendrimers / chemistry*
  • Electrophoretic Mobility Shift Assay
  • Immobilization
  • Injections, Intraperitoneal
  • Male
  • Mice, Inbred C57BL
  • Molecular Dynamics Simulation
  • Muscle Proteins / metabolism
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / pathology*
  • Muscular Atrophy / drug therapy*
  • Muscular Atrophy / prevention & control*
  • Muscular Disorders, Atrophic / drug therapy*
  • Muscular Disorders, Atrophic / pathology
  • Muscular Disorders, Atrophic / prevention & control*
  • Myosin Heavy Chains / metabolism
  • Peptide Fragments / pharmacology
  • Peptide Fragments / therapeutic use*
  • Peptides / therapeutic use
  • SKP Cullin F-Box Protein Ligases / metabolism
  • Static Electricity
  • Tripartite Motif Proteins / metabolism
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Dendrimers
  • Muscle Proteins
  • PAMAM Starburst
  • Peptide Fragments
  • Peptides
  • Tripartite Motif Proteins
  • Angiotensin I
  • Fbxo32 protein, mouse
  • SKP Cullin F-Box Protein Ligases
  • Trim63 protein, mouse
  • Ubiquitin-Protein Ligases
  • Myosin Heavy Chains
  • angiotensin I (1-7)